On Oct 17, 2023,Thermo Fisher announced its plans to acquire Olink. The deal, valued at approximately $3.1 billion or 26 per share, represented a 74% premium over Olink's closing price of $14.98 on Oct 16, 2023. Per Olink, CMA's unconditional approval marks a pivotal step in the acquisition process, signaling regulatory confidence in the merger's compliance with competition laws. This clearance paves the way for Thermo Fisher to expand its portfolio, enhancing its capabilities in the proteomics and genomics ...

The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fisher expect to complete the Offer promptly following the expiration of the Offer at 5:00 p.m. Eastern time on July 9, 2024 ("Expiration Time"). THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, AN ADS LETTER OF TRANSMITTAL, ACCEPTANCE FORM FOR SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMM ...

Core Insights - Olink Holding AB has launched the Olink Target 48 Immune Surveillance, a multiplexed protein assay panel designed for detailed monitoring of the immune system in clinical research [1] - The assay allows detection and quantification of up to 44 biomarkers from just 1μL of sample, and when combined with the Olink Target 48 Cytokine panel, it can analyze up to 89 immune-related proteins using only 2μL [2] - The new product aims to enhance research capabilities in areas such as inflammation, immune response, immuno-oncology, and infectious diseases [2] Product Development and Technology - The Olink Target 48 Immune Surveillance utilizes Olink's PEA™ technology, ensuring high-quality control and validation [3] - The product has been developed in collaboration with the research community to continuously improve its performance [3] Expert Opinions - Experts from the Broad Institute and Massachusetts General Hospital have expressed that the new panels will provide precise quantitative data for analyzing biological pathways and predictive biomarkers, facilitating future oncology trials [4] Global Reach and Research Acceleration - The Olink Target 48 Immune Surveillance is designed to overcome import barriers, streamlining workflows and minimizing maintenance for laboratories [5] - It is compatible with the Olink® Signature Q100 system, enhancing research efficiency through powerful quality control and statistical analysis [5] Strategic Vision - The introduction of this panel is part of Olink's broader portfolio aimed at advancing proteomics solutions across various stages of drug development and disease characterization [7] - The company emphasizes its commitment to precision medicine and the potential of its solutions to provide insights into therapeutic responses and disease progression [6]

UPPSALA, Sweden, May 30, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (NASDAQ:OLK) today reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even preventio ...

Olink Holding AB (publ) Sponsored ADR (OLK) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced a loss of $0.06, delivering a surprise of -142.86%.Over the last four quarters, ...

| | | | Three months ended March 31, | | | --- | --- | --- | --- | --- | | Amounts in thousands of U.S. Dollars | Note | | 2024 | 2023 | | Revenue | 4 | $ | 28,751 $ | 27,457 | | Cost of revenue | | | (11,306) | (9,843) | | Gross profit | | | 17,445 | 17,614 | | Selling expenses | | | (13,903) | (11,995) | | Administrative expenses | | | (19,459) | (16,381) | | Research and development expenses | | | (10,459) | (6,387) | | Other operating income | | | 1,623 | 223 | | Other operating expense | | | (188) | (3 ...

UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 121, with 14 installations during the first quarterTotal Signature Q100 placements reached 202, wi ...

UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income sta ...

Salagatan 16F SE-75330 Uppsala, Sweden Tel: +46 (0) 18-444 39 70 (Address of principal executive offices) With copies to: (Exact name of Registrant as specified in its charter) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR Not Applicable (Translation of Registrant's name into English) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 1 ...

Financial Performance - Revenue for the year ended December 31, 2023, was $169,597,000, representing a 21.3% increase from $139,848,000 in 2022[25]. - Loss after financial items for 2023 was $(39,905,000), compared to a loss of $(15,407,000) in 2022[25]. - Gross profit increased to $114,461,000 in 2023, up from $94,499,000 in 2022, reflecting a gross margin improvement[30]. - Net loss for the period attributable to owners of the company was $31,600,000 in 2023, compared to a loss of $12,851,000 in 2022, indicating a significant increase in losses[30]. - Total comprehensive loss for the period was $15,307,000 in 2023, a substantial improvement from a loss of $73,140,000 in 2022, primarily due to positive foreign exchange differences[30]. - Total financial income for the year ended December 31, 2023, was $11,229 thousand, a decrease from $15,726 thousand in 2022, reflecting a decline of approximately 28.5%[152]. - The company reported a loss before tax of $39,905 thousand for the year ended December 31, 2023, compared to a loss of $15,407 thousand in 2022, indicating a significant increase in losses[155]. - The income tax expense for 2023 was $8,305 thousand, up from $2,556 thousand in 2022, representing an increase of approximately 224%[153]. Assets and Equity - Total assets increased to $602,252,000 in 2023 from $476,290,000 in 2022, reflecting a growth of 26.4%[25]. - Total equity attributable to owners of the company rose to $502,698,000 in 2023, compared to $410,685,000 in 2022, reflecting a solid equity position[31]. - Non-current assets as of December 31, 2023, were valued at $315,707,000, an increase from $293,844,000 in 2022[132]. - As of December 31, 2023, the total goodwill and other intangible assets amounted to $307,589 thousand, with goodwill specifically at $151,693 thousand[164]. Cash and Liquidity - Cash at bank and in hand increased to $120,957,000 as of December 31, 2023, compared to $75,109,000 at the end of 2022, showing improved liquidity[31]. - Cash at bank as of December 31, 2023, was $121.0 million, with restricted cash of $1.4 million and no outstanding loan balances[181]. - The Group's cash is held in Investment Grade credit rated banks, with regular monitoring to mitigate counterparty risk[120]. Employee and Operational Metrics - The number of employees rose to 707 in 2023, up from 582 in 2022, indicating a 21.5% increase[25]. - Employee benefits expenses for the year ended December 31, 2023, totaled $90,212,000, up from $71,252,000 in 2022, marking an increase of approximately 26.7%[140]. - The average number of employees increased from 582 in 2022 to 707 in 2023, representing a growth of approximately 21.5%[142]. Research and Development - Olink plans to continue significant investments in research and development to enhance existing products and develop new solutions[18]. - Research and development expenses increased to $34,183,000 in 2023 from $26,345,000 in 2022, highlighting a commitment to innovation[30]. - The Group conducts research and development on new antibodies for Kit products, expensing unsuccessful development costs as research and development expenses[82]. Sales and Customer Base - The company has served approximately 1,059 customer accounts in over 40 countries, supporting 75% of the world's largest 50 biopharmaceutical companies by 2022 research and development spending[10]. - The Group's sales were concentrated, with 46% of sales in 2023 coming from biopharmaceutical and academia customers based in the Americas[11]. - Revenue from external customers in the United States for 2023 was $73,642,000, accounting for approximately 43.4% of total revenue[130]. Financial Management and Risk - The Group's financial risk management is predominantly controlled by senior management, focusing on minimizing market, credit, and liquidity risks[110]. - The Group applies a simplified approach for expected credit losses (ECL) on trade receivables, recognizing a loss allowance based on lifetime ECLs[84]. - The expected credit loss for trade receivables in 2023 is disclosed in Note 16, indicating a historically low credit loss rate[119]. Lease and Goodwill - The Group's lease liabilities increased from $11,187,000 in 2022 to $32,721,000 in 2023, reflecting a significant rise in financial obligations[122]. - The total lease liabilities as of December 31, 2023, were $26,789 thousand, compared to $9,435 thousand in 2022, indicating a substantial increase in leasing commitments[175]. - The Group has not recorded any impairment charge on goodwill historically, indicating stable asset valuation[104]. Shareholder and Capital Management - The company issued 5,010,253 shares in a public offering in January 2023, raising net proceeds of $96.2 million[194]. - The Group's capital management aims to maximize shareholder value, with continuous reviews of the capital structure based on market conditions and growth rates[123]. - The total number of authorized shares increased to 400,000,000, with 124,342,715 shares issued and outstanding as of December 31, 2023[189].